Literature DB >> 14602742

Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy.

Jochen Mundschenk1, Nicole Unger, Stefan Schulz, Volker Höllt, Solveig Schulz, Rainer Steinke, Hendrik Lehnert.   

Abstract

The stable somatostatin analog octreotide has been successfully used for imaging and treatment of a variety of human tumors. In pheochromocytoma, data on somatostatin receptor subtyping have thus far been sparse. Pheochromocytomas often express more than one somatostatin receptor, and it is uncertain by which receptor subtype the functional responses of octreotide are mediated. Here, we have examined somatostatin receptor protein expression in a panel of 52 pheochromocytomas from 35 randomly selected patients by immunostaining with specific polyclonal anti-sst(1-5) and monoclonal mouse anti-SS-14 antibodies. Staining pattern, distribution and subcellular localization of somatostatin receptor subtypes were investigated. Seventeen patients received (111)In-octreotide scintigraphy. Although the vast majority of tumors (90%) showed positive immunohistochemical staining for sst(3), immunoreactive sst(2A) receptors were only seen in 13 tumors (25%). All other somatostatin receptor subtypes were less frequently detected. Interestingly, among sst(3)-positive tumors strikingly different subcellular distributions of immunoreactive sst(3) receptors were observed. In most cases, immunoreactive sst(3) receptors were distributed throughout the cytosol. Scintigraphic localization of tumors larger than 1 cm in diameter was always successful in the presence of immunoreactive sst(2A) receptors. In the absence of sst(2A), true-positive octreotide scintigraphy was only seen in the presence of membrane-associated sst(3) immunoreactivity. Our findings suggest that selective expression of functional membrane-associated sst(3) receptors is sufficient for high tracer uptake during octreotide scintigraphy in a subgroup of human pheochromocytomas. These tumors may represent a potential target treatment with somatostatin receptor agonists with improved sst(3) activity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14602742     DOI: 10.1210/jc.2003-030262

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  38 in total

1.  Exploring new frontiers in molecular imaging: Emergence of Ga PET/CT.

Authors:  Eik Hock Tan; Soon Whatt Goh
Journal:  World J Radiol       Date:  2010-02-28

Review 2.  Somatostatin receptor scintigraphy in thoracic diseases.

Authors:  P Ameri; F Gatto; M Arvigo; G Villa; E Resmini; F Minuto; G Murialdo; D Ferone
Journal:  J Endocrinol Invest       Date:  2007-11       Impact factor: 4.256

3.  Differential regulation of somatostatin receptor dephosphorylation by β-arrestin1 and β-arrestin2.

Authors:  Andrea Kliewer; Stefan Schulz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-11-26       Impact factor: 3.000

4.  Structural determinants of agonist-selective signaling at the sst(2A) somatostatin receptor.

Authors:  Falko Nagel; Christian Doll; Florian Pöll; Andrea Kliewer; Helmut Schröder; Stefan Schulz
Journal:  Mol Endocrinol       Date:  2011-02-17

5.  Rapid dephosphorylation of G protein-coupled receptors by protein phosphatase 1β is required for termination of β-arrestin-dependent signaling.

Authors:  Florian Pöll; Christian Doll; Stefan Schulz
Journal:  J Biol Chem       Date:  2011-07-27       Impact factor: 5.157

6.  Imaging of gastroenteropancreatic neuroendocrine tumors.

Authors:  Eik Hock Tan; Cher Heng Tan
Journal:  World J Clin Oncol       Date:  2011-01-10

7.  Identification of Phosphorylation Sites Regulating sst3 Somatostatin Receptor Trafficking.

Authors:  Andreas Lehmann; Andrea Kliewer; Thomas Günther; Falko Nagel; Stefan Schulz
Journal:  Mol Endocrinol       Date:  2016-04-21

Review 8.  Current and future therapeutic approaches for metastatic pheochromocytoma and paraganglioma: focus on SDHB tumors.

Authors:  J Matro; A Giubellino; K Pacak
Journal:  Horm Metab Res       Date:  2013-01-15       Impact factor: 2.936

9.  Nonfunctioning benign cardiac pheochromocytoma.

Authors:  Qingbao Li; Quanxin Fan; Decai Li; Haizhou Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2008-06-19       Impact factor: 4.553

10.  Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation.

Authors:  Florian Pöll; Diana Lehmann; Susann Illing; Mihaela Ginj; Stefan Jacobs; Amelie Lupp; Ralf Stumm; Stefan Schulz
Journal:  Mol Endocrinol       Date:  2010-01-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.